Trends in Cardiovascular Medicine
Volume 17, Issue 4 , Pages 140-143 , May 2007

Brain-Derived Neurotrophic Factor: A Newly Described Mediator of Angiogenesis

  • Pouneh Kermani
    • ,
  • Barbara Hempstead

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Dr. Barbara Hempstead, Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA. Tel.: +(1) 212-746-6215; fax: +(1) 212-746-8866

References 

  1. Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 2000;14:2919–2937
  2. Botchkarev VA, Metz M, Botchkareva NV, et al. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 act as “epitheliotrophins” in murine skin. Lab Invest. 1999;79:557–572
  3. Cantarella G, Lempereur L, Presta M, et al. Nerve growth factor–endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J. 2002;16:1307–1309
  4. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389–395
  5. Coppola V, Barrick CA, Southon EA, et al. Ablation of TrkA function in the immune system causes B cell abnormalities. Development. 2004;131:5185–5195
  6. Dolle JP, Rezvan A, Allen FD, et al. Nerve growth factor-induced migration of endothelial cells. J Pharmacol Exp Ther. 2005;315:1220–1227
  7. Donovan MJ, Lin MI, Wiegn P, et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development. 2000;127:4531–4540
  8. Emanueli C, Salis MB, Pinna A, et al. Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation. 2002;106:2257–2262
  9. Epstein SE, Fuchs S, Zhou YF, et al. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards. Cardiovasc Res. 2001;49:532–542
  10. Frade JM, Barde YA. Nerve growth factor: two receptors, multiple functions. Bioessays. 1998;20:137–145
  11. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vasc Biol. 1997;17:1193–1202
  12. Hallbook F, Wilson K, Thorndyke M, Olinski RP. Formation and evolution of the chordate neurotrophin and Trk receptor genes. Brain Behav Evol. 2006;68:133–144
  13. Hempstead BL. The many faces of p75NTR. Curr Opin Neurobiol. 2002;12:260–267
  14. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem. 2003;72:609–642
  15. Isner JM, Vale PR, Symes JF, Losordo DW. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res. 2001;89:389–400
  16. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000;10:381–391
  17. Kermani P, Rafii D, Jin DK, et al. Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. J Clin Invest. 2005;115:653–663
  18. Kraemer R. Reduced apoptosis and increased lesion development in the flow-restricted carotid artery of p75(NTR)-null mutant mice. Circ Res. 2002;91:494–500
  19. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science. 2001;294:1945–1948
  20. Lin MI, Das I, Schwartz GM, et al. TrkC receptor signaling regulates cardiac myocyte proliferation during early heart development in vivo. Dev Biol. 2000;226:180–191
  21. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005;6:603–614
  22. Nemoto K, Fukamachi K, Nemoto F, et al. Gene expression of neurotrophins and their receptors in cultured rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1998;245:284–288
  23. Nykjaer A, Lee R, Teng KK, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature. 2004;427:843–848
  24. Paul CE, Vereker E, Dickson KM, Barker PA. A proapoptotic fragment of the p75 neurotrophin receptor is expressed in p75NTR exonIV null mice. J Neurosci. 2004;24:1917–1923
  25. Robson SC, Kaczmarek E, Siegel JB, et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med. 1997;185:153–163
  26. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays. 2004;26:943–954
  27. Tessarollo L, Tsoulfas P, Donovan MJ, et al. Targeted deletion of all isoforms of the trkC gene suggests the use of alternate receptors by its ligand neurotrophin-3 in neuronal development and implicates trkC in normal cardiogenesis. Proc Natl Acad Sci U S A. 1997;94:14776–14781
  28. Turrin P, Gaetano C, Antonelli A, et al. Nerve growth factor induces angiogenic activity in a mouse model of hindlimb ischemia. Neurosci Lett. 2002;323:109–112
  29. Urbich C, Dernbach E, Aicher A, et al. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 2002;106:981–986
  30. Von Schack D, Casademunt E, Schweigreiter R, et al. Complete ablation of the neurotrophin receptor p75NTR causes defects both in the nervous and the vascular system. Nat Neurosci. 2001;4:977–978
  31. Wagner N, Wagner KD, Theres H, et al. Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms' tumor transcription factor Wt1. Genes Dev. 2005;19:2631–2642

PII: S1050-1738(07)00076-X

doi: 10.1016/j.tcm.2007.03.002

Trends in Cardiovascular Medicine
Volume 17, Issue 4 , Pages 140-143 , May 2007

Article Tools